Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
2.08(c) 2.08(c) 1.93(c) 1.96(c) 1.94(c) Last
1 608 943 3 011 695 2 640 447 1 695 306 1 262 766 Volume
-0.95% 0.00% -7.21% +1.55% -1.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -32,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,34x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -37,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,53x
Yield 2022 -
Capitalization 167 M 167 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 25
Free-Float 96,2%
More Financials
Company
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small... 
More about the company
Ratings of Eloxx Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ELOXX PHARMACEUTICALS, INC.
06/16ELOXX PHARMACEUTICALS  : Financial Statements and Exhibits (form 8-K/A)
AQ
06/15ELOXX PHARMACEUTICALS  : Roche Discloses 5.3% Stake in Eloxx Pharmaceuticals
MT
05/27ELOXX PHARMACEUTICALS  : Announces Funding Award from Cystic Fibrosis Foundation..
PU
05/27ELOXX PHARMACEUTICALS, INC.  : Other Events, Financial Statements and Exhibits (..
AQ
05/27ELOXX PHARMACEUTICALS  : Secures $2.6 Million Funding Award for Development of R..
MT
05/27ELOXX PHARMACEUTICALS  : B. Riley Starts Eloxx Pharmaceuticals at Buy with $5 PT..
MT
05/27Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation..
GL
05/20ELOXX PHARMACEUTICALS, INC.  : Submission of Matters to a Vote of Security Holde..
AQ
05/19ELOXX PHARMACEUTICALS  : Piper Sandler Adjusts Price Target on Eloxx Pharmaceuti..
MT
05/19ELOXX PHARMACEUTICALS  : Announces Closing of Public Offering of Common Stock In..
AQ
05/18ELOXX PHARMACEUTICALS  : Announces Closing of Public Offering of Common Stock In..
PU
05/18ELOXX PHARMACEUTICALS, INC.  : Other Events, Financial Statements and Exhibits (..
AQ
05/18Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common St..
GL
05/18ELOXX PHARMACEUTICALS, INC.  : Entry into a Material Definitive Agreement, Finan..
AQ
05/14ELOXX PHARMACEUTICALS  : Pharma Shares Fall 20% After Pricing Common Stock Offer..
MT
More news
News in other languages on ELOXX PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on ELOXX PHARMACEUTICALS, INC.
More recommendations
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | ELOX | US29014R1032 | MarketScreener
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,94 $
Average target price 4,00 $
Spread / Average Target 106%
EPS Revisions
Managers and Directors
NameTitle
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Tomer Kariv Chairman
Thomas P. Haverty Chief Medical Officer
Vijay Modur Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ELOXX PHARMACEUTICALS, INC.-50.75%169
MODERNA, INC.111.89%88 882
LONZA GROUP AG14.06%52 367
IQVIA HOLDINGS INC.36.17%46 761
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-9.40%28 797